Pharmacist Medication Insights: Cabenuva for HIV


Cabenuva, the first long-acting injectable for the treatment of HIV, is a 2-drug copackaged product containing cabotegravir and rilpivirine.

Among the newest medications for HIV infections, the FDA recently approved cabotegravir and rilpivirine (Cabenuva, ViiV Healthcare), the first injectable regimen for HIV-infected adults, as a monthly injection. Officials also recently approved an oral form of cabotegravir (Vocabria) to be used with rilpivirine 1 month prior to starting therapy with Cabenuva injections.

Recommended dosing with Cabenuva is to begin with cabotegravir 30 mg once daily and rilpivirine 25 mg once daily, then to start Cabenuva 600 mg and rilpivirine 900 mg injection from the second month forward. Health care providers should evaluate the appropriateness of each patient for this therapy, taking into consideration injections, refrigeration, dosing intervals, and adverse effects.

Related Videos
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS |
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz -
Image credit: New Africa |
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages -
Image credit: alicja neumiler |
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image Credit: Pixel-Shot |
Pharmacist holding medicine box and capsule pack in pharmacy drugstore. -- Image credit: I Viewfinder |
© 2024 MJH Life Sciences

All rights reserved.